Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme

Marc Ferrante, Konstantinos Karmiris, Evan Newnham, Jesse Siffledeen, Zuzana Zelinkova, Gert Van Assche, P. Lakatos, Julian Panés, Andreas Sturm, Simon Travis, C. Janneke Van Der Woude, Walter Reinisch, Jean Frédéric Colombel, Remo Panaccione

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and aims: Data on the optimal use of conventional therapies in Crohn's disease are lacking in guidelines. An educational programme was established to explore questions raised in clinical practice and to provide practical answers. Methods: Telephone interviews with 96 gastroenterologists and a web survey of 1370 gastroenterologists identified 26 key questions. Ten questions were taken forward to the next stage based on the opinion of an International Steering Committee. Draft answers to the questions were prepared from available evidence following a literature search. The draft answers were debated in national meetings of participating countries (n = 36) and voted on using a standard scoring system. Revised answers went forward to an international meeting and were debated and voted on using the same methodology. Final answers were developed, based on evidence and clinical experience of the participants. Results: Evidence on corticosteroid and immunomodulator use such as dosage, timing and duration, choice of drug or regimen, and safety is scarce. Key points of the answers included the importance of: identifying patients with poor prognosis; early intervention with optimal doses of immunomodulators; avoiding prolonged or repetitive corticosteroid therapy; achieving corticosteroid-free remission; achieving a balance between clinical benefit and safety when intensifying or prolonging therapy or combining different agents; re-evaluating therapy at appropriate time points; and considering the role of biomarkers and mucosal healing. Conclusions: The answers to 10 key questions were based on available evidence and clinical experience of programme participants. It is hoped they will be of practical use in everyday gastroenterology practice.

Original languageEnglish
Pages (from-to)116-131
Number of pages16
JournalJournal of Crohn's and Colitis
Volume6
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Crohn Disease
Physicians
Adrenal Cortex Hormones
Immunologic Factors
Safety
Gastroenterology
Therapeutics
Biomarkers
Guidelines
Interviews
Surveys and Questionnaires
Pharmaceutical Preparations
Gastroenterologists

Keywords

  • Corticosteroids
  • Crohn's disease
  • Disease management
  • Immunomodulators

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease : Results from an international survey and discussion programme. / Ferrante, Marc; Karmiris, Konstantinos; Newnham, Evan; Siffledeen, Jesse; Zelinkova, Zuzana; Van Assche, Gert; Lakatos, P.; Panés, Julian; Sturm, Andreas; Travis, Simon; Van Der Woude, C. Janneke; Reinisch, Walter; Colombel, Jean Frédéric; Panaccione, Remo.

In: Journal of Crohn's and Colitis, Vol. 6, No. 1, 02.2012, p. 116-131.

Research output: Contribution to journalArticle

Ferrante, M, Karmiris, K, Newnham, E, Siffledeen, J, Zelinkova, Z, Van Assche, G, Lakatos, P, Panés, J, Sturm, A, Travis, S, Van Der Woude, CJ, Reinisch, W, Colombel, JF & Panaccione, R 2012, 'Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme', Journal of Crohn's and Colitis, vol. 6, no. 1, pp. 116-131. https://doi.org/10.1016/j.crohns.2011.09.009
Ferrante, Marc ; Karmiris, Konstantinos ; Newnham, Evan ; Siffledeen, Jesse ; Zelinkova, Zuzana ; Van Assche, Gert ; Lakatos, P. ; Panés, Julian ; Sturm, Andreas ; Travis, Simon ; Van Der Woude, C. Janneke ; Reinisch, Walter ; Colombel, Jean Frédéric ; Panaccione, Remo. / Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease : Results from an international survey and discussion programme. In: Journal of Crohn's and Colitis. 2012 ; Vol. 6, No. 1. pp. 116-131.
@article{7b2df117751c416f80f7f9560ab75d67,
title = "Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme",
abstract = "Background and aims: Data on the optimal use of conventional therapies in Crohn's disease are lacking in guidelines. An educational programme was established to explore questions raised in clinical practice and to provide practical answers. Methods: Telephone interviews with 96 gastroenterologists and a web survey of 1370 gastroenterologists identified 26 key questions. Ten questions were taken forward to the next stage based on the opinion of an International Steering Committee. Draft answers to the questions were prepared from available evidence following a literature search. The draft answers were debated in national meetings of participating countries (n = 36) and voted on using a standard scoring system. Revised answers went forward to an international meeting and were debated and voted on using the same methodology. Final answers were developed, based on evidence and clinical experience of the participants. Results: Evidence on corticosteroid and immunomodulator use such as dosage, timing and duration, choice of drug or regimen, and safety is scarce. Key points of the answers included the importance of: identifying patients with poor prognosis; early intervention with optimal doses of immunomodulators; avoiding prolonged or repetitive corticosteroid therapy; achieving corticosteroid-free remission; achieving a balance between clinical benefit and safety when intensifying or prolonging therapy or combining different agents; re-evaluating therapy at appropriate time points; and considering the role of biomarkers and mucosal healing. Conclusions: The answers to 10 key questions were based on available evidence and clinical experience of programme participants. It is hoped they will be of practical use in everyday gastroenterology practice.",
keywords = "Corticosteroids, Crohn's disease, Disease management, Immunomodulators",
author = "Marc Ferrante and Konstantinos Karmiris and Evan Newnham and Jesse Siffledeen and Zuzana Zelinkova and {Van Assche}, Gert and P. Lakatos and Julian Pan{\'e}s and Andreas Sturm and Simon Travis and {Van Der Woude}, {C. Janneke} and Walter Reinisch and Colombel, {Jean Fr{\'e}d{\'e}ric} and Remo Panaccione",
year = "2012",
month = "2",
doi = "10.1016/j.crohns.2011.09.009",
language = "English",
volume = "6",
pages = "116--131",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease

T2 - Results from an international survey and discussion programme

AU - Ferrante, Marc

AU - Karmiris, Konstantinos

AU - Newnham, Evan

AU - Siffledeen, Jesse

AU - Zelinkova, Zuzana

AU - Van Assche, Gert

AU - Lakatos, P.

AU - Panés, Julian

AU - Sturm, Andreas

AU - Travis, Simon

AU - Van Der Woude, C. Janneke

AU - Reinisch, Walter

AU - Colombel, Jean Frédéric

AU - Panaccione, Remo

PY - 2012/2

Y1 - 2012/2

N2 - Background and aims: Data on the optimal use of conventional therapies in Crohn's disease are lacking in guidelines. An educational programme was established to explore questions raised in clinical practice and to provide practical answers. Methods: Telephone interviews with 96 gastroenterologists and a web survey of 1370 gastroenterologists identified 26 key questions. Ten questions were taken forward to the next stage based on the opinion of an International Steering Committee. Draft answers to the questions were prepared from available evidence following a literature search. The draft answers were debated in national meetings of participating countries (n = 36) and voted on using a standard scoring system. Revised answers went forward to an international meeting and were debated and voted on using the same methodology. Final answers were developed, based on evidence and clinical experience of the participants. Results: Evidence on corticosteroid and immunomodulator use such as dosage, timing and duration, choice of drug or regimen, and safety is scarce. Key points of the answers included the importance of: identifying patients with poor prognosis; early intervention with optimal doses of immunomodulators; avoiding prolonged or repetitive corticosteroid therapy; achieving corticosteroid-free remission; achieving a balance between clinical benefit and safety when intensifying or prolonging therapy or combining different agents; re-evaluating therapy at appropriate time points; and considering the role of biomarkers and mucosal healing. Conclusions: The answers to 10 key questions were based on available evidence and clinical experience of programme participants. It is hoped they will be of practical use in everyday gastroenterology practice.

AB - Background and aims: Data on the optimal use of conventional therapies in Crohn's disease are lacking in guidelines. An educational programme was established to explore questions raised in clinical practice and to provide practical answers. Methods: Telephone interviews with 96 gastroenterologists and a web survey of 1370 gastroenterologists identified 26 key questions. Ten questions were taken forward to the next stage based on the opinion of an International Steering Committee. Draft answers to the questions were prepared from available evidence following a literature search. The draft answers were debated in national meetings of participating countries (n = 36) and voted on using a standard scoring system. Revised answers went forward to an international meeting and were debated and voted on using the same methodology. Final answers were developed, based on evidence and clinical experience of the participants. Results: Evidence on corticosteroid and immunomodulator use such as dosage, timing and duration, choice of drug or regimen, and safety is scarce. Key points of the answers included the importance of: identifying patients with poor prognosis; early intervention with optimal doses of immunomodulators; avoiding prolonged or repetitive corticosteroid therapy; achieving corticosteroid-free remission; achieving a balance between clinical benefit and safety when intensifying or prolonging therapy or combining different agents; re-evaluating therapy at appropriate time points; and considering the role of biomarkers and mucosal healing. Conclusions: The answers to 10 key questions were based on available evidence and clinical experience of programme participants. It is hoped they will be of practical use in everyday gastroenterology practice.

KW - Corticosteroids

KW - Crohn's disease

KW - Disease management

KW - Immunomodulators

UR - http://www.scopus.com/inward/record.url?scp=84855936835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855936835&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2011.09.009

DO - 10.1016/j.crohns.2011.09.009

M3 - Article

C2 - 22261537

AN - SCOPUS:84855936835

VL - 6

SP - 116

EP - 131

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 1

ER -